Your browser doesn't support javascript.
loading
Change of preoperative symptoms of the late-onset hypogonadism syndrome after robot-assisted radical prostatectomy.
Teishima, Jun; Inoue, Shogo; Hayashi, Tetsutaro; Matsubara, Akio.
Afiliação
  • Teishima J; Department of Urology, Graduate School of Biomedical and Health Science, Hiroshima University, Hiroshima, Japan.
  • Inoue S; Department of Urology, Graduate School of Biomedical and Health Science, Hiroshima University, Hiroshima, Japan.
  • Hayashi T; Department of Urology, Graduate School of Biomedical and Health Science, Hiroshima University, Hiroshima, Japan.
  • Matsubara A; Department of Urology, Graduate School of Biomedical and Health Science, Hiroshima University, Hiroshima, Japan.
Curr Urol ; 15(2): 85-90, 2021 Jun.
Article em En | MEDLINE | ID: mdl-34168525
BACKGROUND: As prostate cancer (PCa) is a common cancer among older men, patients with PCa often show aging male symptoms (AMSs). This study aimed to investigate the preoperative AMSs of the late-onset hypogonadism (LOH) syndrome and the effects on them after robot-assisted radical prostatectomy (RARP). MATERIALS AND METHODS: One hundred eighty-eight patients who underwent RARP without androgen deprivation therapy were measured for serum free and serum total testosterone, and were preoperatively assessed for symptoms of the LOH syndrome using a questionnaire containing an AMS score. Patients with a preoperative AMS score higher than 37 and a serum free testosterone level lower than 8.5 pg/mL were classified as Group A, with the remaining classified as Group B. AMS scores were measured at 1, 3, 6, 9, and 12 months after surgery. RESULTS: Of the 188 patients, 49 and 139 patients were classified as Groups A and B, respectively. Preoperative AMS scores were 44.5 ±â€Š8.2 in Group A and 28.6 ±â€Š5.3 in Group B (p < 0.0001). AMS scores in Group A significantly improved 1 month after RARP (30.6 ±â€Š8.4, p < 0.0001) compared with their preoperative scores and remained at the same level from 3 to 12 months postoperatively, whereas those in Group B became significantly worse (32.0 ±â€Š7.8, p < 0.0001) than their preoperative ones. There were no differences between AMS scores in Groups A and B at every postoperative period (p = 0.3259, 0.2730, 0.2429, 0.4629, 0.1771 at 1, 3, 6, 9, and 12 months after surgery, respectively). CONCLUSIONS: Our results indicate that AMSs in PCa patients with the LOH syndrome can expect the same level of improvement as patients without it.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article